• Vania Mozetic, Rafael Leite Pacheco, Carolina de Oliveira Cruz Latorraca, Fernanda Chin Yu Ogasawara Lee, João Victor Borges Gomes, and Rachel Riera.
• MD. Ophthalmologist, Instituto Dante Pazzanese de Cardiologia, São Paulo (SP), Brazil.
• Sao Paulo Med J. 2019 Nov 1; 137 (6): 530542530-542.

BackgroundAge-related macular degeneration (AMD) is the third largest cause of blindness worldwide, accounting for 8.7% of all cases. A considerable number of preventive or therapeutic interventions have been used for AMD.ObjectiveThis study presents a critical view of the interventions that have been assessed through Cochrane systematic reviews.Design And SettingReview of systematic reviews, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP).MethodsReview of Cochrane systematic reviews about interventions for AMD.ResultsThe 18 systematic reviews included assessed the effects of surgical techniques, laser/photo/radiotherapy, intravitreal injections, systemic drugs and phytotherapy/vitamins/supplements.ConclusionThe Cochrane systematic reviews found evidence that use of bevacizumab, ranibizumab, pegaptanib, laser photocoagulation, photodynamic therapy and multivitamin compounds may present some benefits for treating AMD. There was insufficient evidence for supporting the use of macular translocation, submacular surgery, steroid implantation, radiotherapy, intravitreal aflibercept, interferon alfa, statins or omega-3 fatty acids for treating AMD; or the use of multivitamin antioxidant vitamins or mineral supplementation for preventing AMD. Future randomized controlled trials are imperative to reduce the uncertainty in several clinical questions regarding AMD.

14 keywords...

hide…